DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

24-hour IOP-lowering Effect of Brimonidine 0.1%

Information source: Allergan
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Open-angle Glaucoma; Ocular Hypertension

Intervention: brimonidine 0.1% (Alphagan® P) (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Allergan

Official(s) and/or principal investigator(s):
Medical Affairs, Study Director, Affiliation: Allergan


This study will evaluate the efficacy and safety of brimonidine 0. 1% three-times daily in patients with glaucoma or ocular hypertension

Clinical Details

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Intraocular Pressure (IOP) for a 24-Hour Period at Week 4

Secondary outcome:

Change From Baseline in Intraocular Pressure (IOP) for a 24-Hour Period at Week 4

Ocular Perfusion Pressure (OPP) for a 24-Hour Period at Week 4

Change in Ocular Perfusion Pressure (OPP) Over a 24-Hour Period at Week 4


Minimum age: 40 Years. Maximum age: 80 Years. Gender(s): Both.


Inclusion Criteria:

- patients with open-angle glaucoma or ocular hypertension

Exclusion Criteria:

- allergy to brimonidine

- inability to complete 24 hour stay for monitoring

Locations and Contacts

San Diego, California, United States
Additional Information

Starting date: December 2006
Last updated: October 18, 2011

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017